Sign in

DMAA on Nasdaq

Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. is a blank check company, listed on Nasdaq (DMAA).1 It is headquartered in New York, New York.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerDMAA on Nasdaq1
  • IndustryBlank Checks1
  • HeadquartersNew York, New York1
  • Business address420 Lexington Avenue, Suite 1402, New York, Ny 101702
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Agreement”) with Titan Advisory Services LLC for the provision of such principal financial and accounting officer services by Mr.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Every line of the income statement as filed: the last 1 fiscal year, latest first.4

Period ending2025-12-31
General and administrative costs$2.8M
Loss from operations-$2.8M
Interest earned on cash and investments held in Trust Account$8.8M
Total other income$8.8M
NET INCOME (LOSS)$5.9M

Compare Drugs Made In America Acquisition Corp. with another company

Corporate structure

Drugs Made In America Acquisition Corp. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Drugs Made In America Acquisition Corp.

  • Drugs Made In America Acquisition Corp. New York, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Drugs Made In America Acquisition Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

We do not own any real estate or other physical properties materially important to our operations. Our principal executive offices were previously located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301. The cost for this space is included in the $10,000 per month fee that we will pay to our sponsor or an affiliate for office space, administrative and support services. We have ceased making the $10,000 per month fee as the agreement has been cancelled in March 2026. Our current principal executive offices are located at 420 Lexington Avenue, Suite 1402, New York, NY 10170. We consider our current office space adequate for our current operations.

Item 2 of the 10-K filed Apr 15, 2026.3

Leadership

Who has led Drugs Made In America Acquisition Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lynn Stockwell2025

Chair

  1. Lynn Stockwell2025

Chief financial officer

  1. Glenn C. Worman2025
Board members and other officers (5)

Timeline

  1. Sep 14, 20268-K Entered a material agreement14
  2. Jul 20, 20268-K Entered a material agreement15
  3. May 5, 20268-K Entered a material agreement16
  4. May 1, 20268-K Bylaws or fiscal year changed; Shareholder vote; Other events17
  5. Apr 28, 20268-K Entered a material agreement18
  6. Apr 8, 20268-K Other events19
  7. Mar 27, 20268-K Entered a material agreement; New debt or obligation; Other events20
  8. Mar 6, 20268-K Executive or director change21
  9. Mar 6, 20268-K Other events22
  10. Nov 18, 20258-K Executive or director change23
  11. Feb 25, 20258-K Unregistered sale of shares; Other events24
  12. Feb 24, 20258-K Other events25
  13. Feb 4, 2025New chief executive Lynn Stockwell becomes CEO7

Filings

78 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 14 major events, 14 insider forms, 14 large holders, 29 other. The latest 20:

  1. Sep 14, 2026425 CURRENT REPORT EDGAR
  2. Sep 14, 20268-K CURRENT REPORT EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 13, 2026SCHEDULE 13G/A EDGAR
  7. Aug 13, 2026SCHEDULE 13G/A EDGAR
  8. Jul 20, 2026425 CURRENT REPORT EDGAR
  9. Jul 20, 20268-K CURRENT REPORT EDGAR
  10. Jun 26, 2026SCHEDULE 13G EDGAR
  11. May 14, 202610-Q QUARTERLY REPORT EDGAR
  12. May 14, 2026SCHEDULE 13G EDGAR
  13. May 5, 2026425 CURRENT REPORT EDGAR
  14. May 5, 20268-K CURRENT REPORT EDGAR
  15. May 1, 20268-K CURRENT REPORT EDGAR
  16. Apr 28, 20268-K CURRENT REPORT EDGAR
  17. Apr 16, 2026DEFR14A REVISED DEFINITIVE PROXY STATEMENT EDGAR
  18. Apr 15, 202610-K ANNUAL REPORT EDGAR
  19. Apr 14, 2026DEF 14A PROXY STATEMENT EDGAR
  20. Apr 8, 20268-K CURRENT REPORT EDGAR

The 78 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 4 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 18, 2025Drugs Made In America Acquisition LLC10% ownerBuy30,000Form 4
Feb 18, 2025Stockwell LynnCEO and Exe. Chair of BoardBuy30,000Form 4
Jan 29, 2025Drugs Made In America Acquisition LLC10% ownerBuy400,000Form 4
Jan 29, 2025Drugs Made In America Acquisition LLC10% ownerSale5,698,363Form 4
Jan 29, 2025Stockwell LynnCEO and Exe. Chair of BoardBuy400,000Form 4
Jan 29, 2025Stockwell LynnCEO and Exe. Chair of BoardSale5,698,363Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Drugs Made In America Acquisition Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDrugs Made In America Acquisition Corp.1
  • CIK0002028614
  • Employer ID (EIN)99-23947883
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inCayman Islands3
  • Fiscal year endsDecember 311
  • Industry code (SIC)6770 Blank Checks1
  • SEC reviewing officeOffice of Real Estate & Construction, Division of Corporation Finance1
  • Business address420 Lexington Avenue, Suite 1402, New York, NY 101701
  • Phone646-726-70741
  • Shares outstanding24,276,913 as of Aug 14, 20266
  • Public float$234.6M as of Jun 30, 20253
  • AuditorMaloneBailey, LLP, Houston, Texas PCAOB ID 206; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceAug 1, 20241
  • Filings78 in all: 8-K (14), 4 (8), SCHEDULE 13G (7), 3 (6), S-1/A (6), SCHEDULE 13G/A (6), 10-Q (5), CORRESP (5)1
    All 23 form types

    425 (3), 10-K (2), EFFECT (2), NT 10-Q (2), POS AM (2), 424B4 (1), 8-A12B (1), CERT (1), DEF 14A (1), DEFR14A (1), NT 10-K (1), PRE 14A (1), S-1 (1), SCHEDULE 13D (1), UPLOAD (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Apr 14, 2026
    Latest 8-K (8-K) Sep 14, 2026

Securities registered for trading

ClassSymbolExchange
Units, each consisting of one Ordinary Share, par value $0.0001 per share, and one Right to receive one-eighth (1/8) of an Ordinary ShareDMAAUThe Nasdaq Stock Market LLC
Ordinary SharesDMAAThe Nasdaq Stock Market LLC
RightsDMAARThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

Legal proceedings

We may be subject to legal proceedings, investigations and claims incidental to the conduct of our business from time to time. There is currently no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such, and we and the members of our management team have not been subject to any such proceeding.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
    SEC EDGAROther events
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33